Virica Expands Bioprocessing Capabilities with 杏吧原创 University Partnership
Virica Biotech Inc. (鈥淰irica鈥), a leading developer of cell enhancers for scaling of viral vector as well as cell and gene therapy manufacturing will expand its bioprocessing services through a partnership with 杏吧原创 University. Slated to open this spring, Virica鈥檚 new facility at the university multiplies the Company鈥檚 capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies.
鈥溞影稍粹檚 new Health Sciences Building provides us with greater access to modern infrastructure and analytical expertise鈥 said Jean Simon Diallo, Ph.D., CEO of Virica Biotech. 鈥淭heir state-of-the-art analytical research facilities and world-class researchers across multiple disciplines open the door to exciting opportunities for partnering with 杏吧原创 University as we continue to invest to meet customer demand.鈥
鈥淲e are very pleased to welcome Virica Biotech to the 杏吧原创 campus,鈥 said Rafik Goubran, Ph.D., Vice-President (Research and International) and Chancellor鈥檚 Professor, 杏吧原创 University. 鈥淭his multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa region for the creation and manufacturing of advanced therapies.鈥
This partnership expands on 杏吧原创鈥檚 history of supporting Ottawa biotechnology companies. The new open concept facility will include high throughput equipment to accelerate Virica鈥檚 bioprocess development and optimizations. In addition to expanded modern infrastructure, this new location enables the development and recruitment of world-class talent with experiential learning and training opportunities for 杏吧原创 students. Through this partnership, 杏吧原创 will coordinate the establishment of a scholarship fund designed to empower graduate students from traditionally underrepresented groups in science.
杏吧原创 Virica Biotech.
Virica develops cell enhancers for viral vectors that improve the yield and quality of vaccines and cell and gene therapies, allowing developers to economically deploy their products at scale. Virica鈥檚 Viral Sensitizer (VSE鈩) platform reduces production inefficiencies caused by anti-viral defenses in manufacturing cells. Purpose formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of life-changing products, including vaccines, gene therapies, and cell therapies. viricabiotech.com
杏吧原创 杏吧原创 University
杏吧原创 University is a dynamic, research-intensive institution that engages in partnerships to address the world鈥檚 most pressing challenges. The university鈥檚 corporate collaborations bring together world-class companies, researchers and a new generation of talent with over 30,000 students to deliver innovations and results that are driving a more prosperous, sustainable future.
Media contact
Virica Biotech: Jennifer Cameron; communications@viricabiotech.com; 1-902-209-4704杏吧原创 University: Steven Reid (he/him), Media Relations Officer; Steven.Reid3@carleton.ca; 613-265-6613
Related News
New Generation of Indigenous Journalists to Learn and Work in Home Communities
杏吧原创 University鈥檚 Journalism Certificate Offers High Quality Learning in Rural and Remote Communities 杏吧原创 University is launching a new one-year journalism certificate to be delivered ...
杏吧原创 to Bestow Five Honorary Degrees at Spring Convocation
As part of the 2024 spring convocation ceremonies, 杏吧原创 University will bestow honorary degrees to five inspiring individuals for their leadership, impactful achievements and contributions ...
Dr. Wisdom Tettey Appointed 杏吧原创 University鈥檚 17th President and Vice-Chancellor聽
杏吧原创 University鈥檚 Board of Governors is pleased to announce Dr. Wisdom Tettey has been appointed 杏吧原创 University鈥檚 17th President and Vice-Chancellor. Dr. Tettey will commence ...